替莫唑胺与司莫司汀对胶质母细胞瘤的临床疗效比较  

Comparative study of clinical efficacy of emozolomide and semustine on glioblastoma

作　　者：朱颂华[1] 陆泳宇 

机构地区：[1]海门市人民医院脑外科,江苏海门226100

出　　处：《河南医学研究》2015年第12期18-20,共3页Henan Medical Research

摘　　要：目的比较替莫唑胺与司莫司汀在胶质母细胞瘤切除术后化疗中的临床疗效。方法将海门市人民医院收治的80例胶质母细胞瘤患者随机分为治疗组和对照组,各40例。治疗组给予替莫唑胺治疗,对照组给予司莫司汀治疗。比效两组患者的未进展存活率、KPS评分、半年复发率及药物不良反应。结果治疗组患者第2、4、6疗程后未进展存活率均高于对照组(P<0.05);治疗后,两组KPS评分显著增加,治疗组KPS评分显著高于对照组(P<0.05);治疗组半年复发率显著低于对照组(P<0.05);治疗组患者不良反应发生率明显低于对照组(P<0.05)。结论替莫唑胺能有效治疗胶质母细胞瘤,提高患者生存率,减少不良反应。Objective To compare the clinical efficacy of temozolomide and semustine on glioblastoma after resection. Methods 80 patients with glioblastoma in the People＇ s Hospital of Haimen were randomly divided into treatment group （40 cases） and control group （40 cases） . Patients in treatment group received temozolomide, and patients in control group were treated wtih semustine. The survivals, KPS scores, and adverse events of two groups were compared. Results The survivals without progression at 2, 4, 6 months in treatment group were significantly higher than control group （ P 〈 0.05 ）. The KPS scores of two groups were significantly increased after treatment, and the KPS score of treatment group was significantly higher than control group（P 〈 0.05 ）. During 6 - month follow - up, the recurrence rate in treatment group was lower than control group （ P 〈 0. 05 ）. The adverse events in treatment group was significantly lower than control group （ P 〈 0.05 ）. Conclusion Temozolomide is effective in the treatment of glioblastoma with higher survival and lower adverse events.

关 键 词：替莫唑胺 司莫司汀 胶质母细胞瘤 临床疗效 

分 类 号：R739.4[医药卫生—肿瘤]